Global Inhaled Nitric Oxide Market to Reach $1,732.93 Million by 2033: Key Trends and Growth Forecast

Market Size & Growth

• Market Size (2024): USD 1,002.83 Million
• Projected Market Size (2033): USD 1,732.93 Million
• Compound Annual Growth Rate (CAGR) (2025-2033): 5.64%

Key Market Drivers:

• Neonatal Care & Respiratory Distress
• Cardiopulmonary Applications & Critical Care
• Technological Advancements & Personalized Therapy

Emerging Trends

• Integration With Portable Delivery Systems
• Focus On Personalized Respiratory Therapy
• Increasing Collaborations And Strategic Partnerships

Segmentation Highlights

• Analysis By Application
• Regional Analysis

Market Overview:

According to IMARC Group's latest research publication, the global inhaled nitric oxide market size was valued at USD 1,002.83 Million in 2024. Looking forward, IMARC Group estimates the market to reach USD 1,732.93 Million by 2033, exhibiting a CAGR of 5.64% from 2025-2033.

This detailed analysis primarily encompasses industry size, business trends, market share, key growth factors, and regional forecasts. The report offers a comprehensive overview and integrates research findings, market assessments, and data from different sources. It also includes pivotal market dynamics like drivers and challenges, while also highlighting growth opportunities, financial insights, technological improvements, emerging trends, and innovations. Besides this, the report provides regional market evaluation, along with a competitive landscape analysis.

Claim Your Free "Inhaled Nitric Oxide Market" Analysis Sample Report Here

Our report includes:

• Market Dynamics
• Market Trends and Market Outlook
• Competitive Analysis
• Industry Segmentation
• Strategic Recommendations

Growth Factors in the Inhaled Nitric Oxide Industry:

• Neonatal Care & Respiratory Distress

Neonatal applications continue to be a cornerstone for inhaled nitric oxide (iNO) therapy, particularly in treating infants with persistent pulmonary hypertension (PPHN). Advanced NICUs are expanding their protocols to integrate iNO earlier in care pathways, improving oxygenation without escalating to more invasive interventions. In countries like Canada and Sweden, healthcare providers are implementing transport-ready iNO units to ensure continuity of care during critical transfers. There’s also growing emphasis on blending iNO with CPAP and other non-invasive respiratory support, reducing the need for mechanical ventilation. Meanwhile, pediatric hospitals are focusing on real-time monitoring tools to manage dosage more precisely and reduce complications. Increased training initiatives for neonatologists and respiratory therapists are spreading awareness and boosting adoption in mid-tier hospitals. However, equitable access remains an issue in low-income and rural regions, prompting global efforts to develop cost-effective, easy-to-use iNO systems tailored for remote neonatal care environments.

• Cardiopulmonary Applications & Critical Care

iNO therapy is expanding rapidly in adult critical care, with cardiopulmonary applications emerging as a major driver. ICUs in the US, Germany, and South Korea are deploying iNO for acute respiratory failure, particularly in ARDS and COVID-related complications, to improve ventilation-perfusion matching. These protocols often incorporate iNO alongside ECMO and prone positioning strategies for enhanced gas exchange. In cardiovascular care, post-surgical patients benefit from iNO’s ability to reduce pulmonary vascular resistance, especially after valve replacements and heart transplants. Leading hospitals are integrating iNO modules into centralized ventilator systems, allowing seamless dose management across multiple devices. Interest is growing in using iNO to manage right ventricular dysfunction and pulmonary hypertension in heart failure patients. Despite clinical gains, barriers around cost, staffing, and training persist in community hospitals. Digital simulation tools and cloud-based training platforms are being introduced to bridge these knowledge and infrastructure gaps, supporting wider adoption.

• Technological Advancements & Personalized Therapy

Technological upgrades are transforming inhaled nitric oxide therapy into a precision-focused treatment. Smart delivery platforms now incorporate sensors that auto-adjust dosing based on respiratory patterns, oxygenation levels, and patient body weight. These innovations are gaining popularity in tertiary care hospitals across Singapore, the US, and Scandinavia, where real-time analytics guide decision-making. Companies are rolling out Bluetooth-enabled devices that sync with mobile dashboards, enabling physicians to remotely monitor flow rates and treatment adherence. AI-powered software is even being used to predict iNO response curves, tailoring regimens to patient-specific lung mechanics. Startups are exploring miniaturized cartridges and zero-calibration interfaces to simplify usage in home settings. Despite these breakthroughs, many hospitals still face interoperability issues when integrating iNO with legacy EHR systems. Vendors are now prioritizing plug-and-play compatibility, ensuring new devices can be deployed quickly across various care environments while maintaining safety and data integrity.

Key Trends in the Inhaled Nitric Oxide Market:

• Integration With Portable Delivery Systems

Portable iNO devices are transforming treatment accessibility, especially for patients requiring extended therapy outside the ICU. New units are compact, lightweight, and battery-powered, making them ideal for ambulatory care or transitional settings like step-down units and long-term rehabilitation centers. Companies are embedding smart features like GPS tracking, wireless data upload, and automated refill alerts to streamline device management. Homecare integration is gaining popularity in markets such as the UK and Japan, where hybrid care models are being adopted to ease hospital congestion. Patients with chronic lung diseases, such as pulmonary fibrosis or COPD with pulmonary hypertension, are benefiting from these advances. Remote supervision by respiratory specialists allows for dose titration without in-person visits. These systems are also aiding resource-limited hospitals by reducing the need for bulky stationary equipment. As healthcare systems push toward decentralization, portable iNO will play a critical role in expanding equitable care access.

• Focus On Personalized Respiratory Therapy

The shift toward personalized medicine is creating new use cases for tailored iNO therapy. Hospitals are leveraging connected devices to gather real-time respiratory data—such as flow rate, oxygenation index, and airway pressure—which feed into AI algorithms that recommend precise dosing regimens. Ventilator-linked iNO platforms now allow therapy to be adapted dynamically in response to fluctuations in lung mechanics, particularly valuable in cases of fluctuating ARDS or multi-organ dysfunction. Some institutions are experimenting with biomarker-based stratification to predict iNO response, helping determine which patients are most likely to benefit. Clinicians are also customizing delivery modes depending on patient demographics, such as adjusting flow for pediatric versus adult patients. As therapy personalization improves, clinicians report reduced length of ICU stay and better weaning outcomes. These advances are bringing iNO in line with broader precision respiratory therapies, encouraging further innovation in this direction.

• Increasing Collaborations And Strategic Partnerships

Strategic alliances are accelerating development in the iNO space, with pharmaceutical companies teaming up with medical device innovators to produce integrated solutions. Collaborations between software developers and ventilator manufacturers have led to the launch of intelligent dosing systems that sync across platforms. In regions like China and India, government-backed initiatives are supporting public-private partnerships to develop low-cost, high-efficiency delivery devices suitable for rural deployment. Academic institutions are licensing out novel nitric oxide compounds designed for prolonged-release formats or disease-specific targeting. Hospital networks in North America are conducting joint pilots with startups to trial AI-driven dosing tools, with real-world results informing broader deployment strategies. These partnerships are not only cutting time-to-market but also enabling compliance with evolving regulatory standards. As the demand for flexible, tech-enabled respiratory solutions grows, cross-sector collaboration is expected to remain a linchpin for sustained market momentum.

Unlock Exclusive Insights—Buy the Full Report with a Discount!

Leading Companies Operating in the Global Inhaled Nitric Oxide Industry:

• Air Liquide S.A
• Bellerophon Therapeutics
• Beyond Air Inc.
• Linde plc
• Mallinckrodt plc
• Merck KGaA
• Novoteris LLC
• Nu-Med Plus
• VERO Biotech LLC

Inhaled Nitric Oxide Market Report Segmentation: 

Analysis By Application:

• Neonatal Respiratory Treatment
• Chronic Obstructive Pulmonary Disease (COPD)
• Acute Respiratory Distress Syndrome (ARDS)
• Others

Neonatal respiratory treatment represents the largest market share as premature infants are at high risk of developing respiratory distress syndrome (RDS), necessitating prompt and effective intervention.

Regional Insights:

• North America (United States, Canada)
• Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, Others)
• Europe (Germany, France, United Kingdom, Italy, Spain, Russia, Others)
• Latin America (Brazil, Mexico, Others)
• Middle East and Africa

Research Methodology:

The report employs a comprehensive research methodology, combining primary and secondary data sources to validate findings. It includes market assessments, surveys, expert opinions, and data triangulation techniques to ensure accuracy and reliability.

Note: If you require specific details, data, or insights that are not currently included in the scope of this report, we are happy to accommodate your request. As part of our customization service, we will gather and provide the additional information you need, tailored to your specific requirements. Please let us know your exact needs, and we will ensure the report is updated accordingly to meet your expectations.

About Us:

IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provide a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.

Contact Us:

IMARC Group

134 N 4th St. Brooklyn, NY 11249, USA

Email: [email protected]

Tel No:(D) +91 120 433 0800

United States: +1–201971–6302